sisomicin
ApprovedWithdrawn 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pyoderma
Conditions
Pyoderma
Trial Timeline
May 1, 2007 → Sep 1, 2007
NCT ID
NCT00202891About sisomicin
sisomicin is a approved stage product being developed by Merck for Pyoderma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00202891. Target conditions include Pyoderma.
What happened to similar drugs?
0 of 5 similar drugs in Pyoderma were approved
Approved (0) Terminated (4) Active (1)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00202891 | Approved | Withdrawn |
Competing Products
11 competing products in Pyoderma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ixekizumab | Eli Lilly | Phase 2 | 35 |
| adalimumab | AbbVie | Phase 3 | 40 |
| secukinumab 150 mg (2 injections per dose | Novartis | Phase 2 | 27 |
| Secukinumab | Novartis | Phase 1/2 | 32 |
| Deucravacitinib | Bristol Myers Squibb | Phase 1 | 21 |
| gevokizumab | XOMA | Phase 2 | 25 |
| gevokizumab + Placebo + gevokizumab open-label | XOMA | Phase 3 | 22 |
| gevokizumab | XOMA | Phase 3 | 22 |
| gevokizumab + Placebo + gevokizumab open-label | XOMA | Phase 3 | 22 |
| vilobelimab + Placebo | InflaRx | Phase 3 | 22 |
| vilobelimab | InflaRx | Phase 2 | 25 |